A new study by the Kidney Cancer Research Alliance (KCCure) has found that kidney cancer patients prioritize efficacy over cost when choosing therapy.
The study, which surveyed over 1,000 metastatic kidney cancer patients, found that the top two factors patients considered when choosing therapy were the opportunity for a complete response (CR) and long-term efficacy. Cost and toxicity were the least important factors.
The findings of this study are significant because they highlight the importance of patient-centered decision-making in the treatment of kidney cancer. Patients want to be cured of their disease, and they are willing to accept some risk of toxicity if it means they have a better chance of achieving a CR.
The study also found that patients are increasingly aware of the different treatment options available for kidney cancer. In particular, patients are more likely to be aware of targeted therapies and immunotherapy, which are newer treatment options that have shown promise in clinical trials.
The findings of this study have implications for both patients and healthcare providers. Patients should be aware of their treatment options and the factors that are most important to them when making a decision about therapy. Healthcare providers should discuss these factors with patients and help them make an informed decision about the best treatment option for their individual situation.
Keywords: kidney cancer, therapy selection, efficacy, cost, toxicity, patient-centered decision-making
Comments
Post a Comment